- ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
Following speculation that Sarepta Therapeutics's (SRPT) muscular dystrophy therapy is struggling to gain approval, Janney highlighted downside risk to the stock.
Sarepta (SRPT) stock is advancing in afternoon trading after a government website indicated the biopharmaceutical company is recruiting patients in its Phase III trials to treat Duchenne muscular dystrophy.